Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies

Lung Cancer

Volumn 63, Issue 3, 2009, Pages 418-424

  Ito, Takeo ^a,b   Ishii, Genichiro ^a   Nagai, Kanji ^a   Nagano, Tatsuya ^a   Kojika, Masakazu ^a   Murata, Yukinori ^a   Atsumi, Naho ^a   Nishiwaki, Yutaka ^a   Miyazaki, Eishi ^b   Kumamoto, Toshihide ^b   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

D2 40; Immunohistochemistry; Lung cancer; Podoplanin; Prognosis; Squamous cell carcinoma; Stage IB; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; PODOPLANIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TISSUE SECTION; UNIVARIATE ANALYSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 59249105807     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.06.008     Document Type: Article

References (24)

1. Goya T., Asamura H., Yoshimura H., Kato H., Shimokata K., Tsuchiya R., et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50 (2005) 227-234
2. Wu S., Sato M., Endo C., Sakurada A., Dong B., Aikawa H., et al. hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. Lung Cancer 41 (2003) 179-186
3. Werle B., Lotterle H., Schanzenbacher U., Lah T.T., Kalman E., Kayser K., et al. Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients. Br J Cancer 81 (1999) 510-519
4. Villegas F.R., Coca S., Villarrubia V.G., Jimenez R., Chillon M.J., Jareno J., et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35 (2002) 23-28
5. Funai K., Yokose T., Ishii G., Araki K., Yoshida J., Nishimura M., et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 27 (2003) 978-984
6. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
7. Nishiwaki Y., Yano S., Tamura T., Nakagawa K., Kudoh S., Horai T., et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib. Gan To Kagaku Ryoho 31 (2004) 567-573
8. Chang A., Parikh P., Thongprasert S., Tan E.H., Perng R.P., Ganzon D., et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 1 (2006) 847-855
9. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
10. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
11. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
12. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
13. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
14. Kato H., Ichinose Y., Ohta M., Hata E., Tsubota N., Tada H., et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 (2004) 1713-1721
15. Hamada C., Tanaka F., Ohta M., Fujimura S., Kodama K., Imaizumi M., et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23 (2005) 4999-5006
16. Pisters K.M., Evans W.K., Azzoli C.G., Kris M.G., Smith C.A., Desch C.E., et al. Cancer Care Ontario and American Society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J Clin Oncol (2007)
17. Suzuki K., Nagai K., Yoshida J., Nishimura M., Takahashi K., Yokose T., et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 86 (1999) 1976-1984
18. Shimizu K., Yoshida J., Nagai K., Nishimura M., Ishii G., Morishita Y., et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 130 (2005) 160-165
19. Giatromanolaki A., Koukourakis M.I., Sivridis E., Pastorek J., Wykoff C.C., Gatter K.C., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61 (2001) 7992-7998
20. Martin-Villar E., Scholl F.G., Gamallo C., Yurrita M.M., Munoz-Guerra M., Cruces J., et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113 (2005) 899-910
21. Kato Y., Kaneko M., Sata M., Fujita N., Tsuruo T., and Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 26 (2005) 195-200
22. Yuan P., Temam S., El-Naggar A., Zhou X., Liu D.D., Lee J.J., et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107 (2006) 563-569
23. Dumoff K.L., Chu C., Xu X., Pasha T., Zhang P.J., and Acs G. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 18 (2005) 97-104
24. Kunita A., Kashima T.G., Morishita Y., Fukayama M., Kato Y., Tsuruo T., et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170 (2007) 1337-1347